Clinical Trials Directory

Trials / Completed

CompletedNCT02440633

A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
8 (actual)
Sponsor
Otsuka Pharmaceutical Co., Ltd. · Industry
Sex
Male
Age
35 Years – 55 Years
Healthy volunteers
Accepted

Summary

To obtain absorption, metabolism and excretion data for parent drug and any metabolites.

Conditions

Interventions

TypeNameDescription
DRUG14C-OPS-2071Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.

Timeline

Start date
2015-05-01
Primary completion
2015-08-01
Completion
2015-08-01
First posted
2015-05-12
Last updated
2016-10-21
Results posted
2016-08-24

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT02440633. Inclusion in this directory is not an endorsement.